QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
4D Molecular Therapeutics
(NASDAQ:FDMT)
7.81
0.44[5.97%]
At close: May 20
7.81
00
After Hours: 4:04PM EDT
Day High/Low7.33 - 7.82
52 Week High/Low7.13 - 36.14
Open / Close7.55 / 7.81
Float / Outstanding25.9M / 32.3M
Vol / Avg.354.8K / 208.5K
Mkt Cap252.3M
P/E-
50d Avg. Price12.87
Div / Yield-
Payout Ratio-
EPS-0.82
Total Float25.9M

4D Molecular Therapeutics (NASDAQ:FDMT), Quotes and News Summary

4D Molecular Therapeutics (NASDAQ: FDMT)

Day High/Low7.33 - 7.82
52 Week High/Low7.13 - 36.14
Open / Close7.55 / 7.81
Float / Outstanding25.9M / 32.3M
Vol / Avg.354.8K / 208.5K
Mkt Cap252.3M
P/E-
50d Avg. Price12.87
Div / Yield-
Payout Ratio-
EPS-0.82
Total Float25.9M
Benzinga - May 13, 2022, 4:52AM
Benzinga - May 12, 2022, 4:07PM
Benzinga - Apr 4, 2022, 4:02PM
Benzinga - Mar 28, 2022, 4:03PM
Benzinga - Feb 9, 2022, 12:56PM
Benzinga - Feb 9, 2022, 8:08AM
Benzinga - Jan 10, 2022, 8:04AM
Benzinga - Jan 6, 2022, 4:03PM
Benzinga - Jan 4, 2022, 6:05AM
Benzinga - Nov 10, 2021, 4:26PM
Benzinga - Oct 29, 2021, 3:13PM
Benzinga - Oct 26, 2021, 5:58PM
load more
Sector: Health Care.Industry: Biotechnology
4D Molecular Therapeutics Inc a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built portfolio of gene therapy product candidates focused in three therapeutic areas: ophthalmology (intravitreal vector), cardiology (intravenous vector) and pulmonology (aerosol vector). It has three product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa in a Phase 1/2 clinical trial, 4D-110 for the treatment of choroideremia in a Phase 1 clinical trial, and 4D-310 for the treatment of Fabry disease in a Phase 1/2 clinical trial. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration, and 4D-710 for the treatment of cystic fibrosis lung disease.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-11
REV
Q1 2022Est.ActualSurprise
EPS-0.820
REV1.219M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

4D Molecular Therapeutics Questions & Answers

Q
How do I buy 4D Molecular Therapeutics (FDMT) stock?
A

You can purchase shares of 4D Molecular Therapeutics (NASDAQ: FDMT) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are 4D Molecular Therapeutics's (FDMT) competitors?
Q
What is the target price for 4D Molecular Therapeutics (FDMT) stock?
A

The latest price target for 4D Molecular Therapeutics (NASDAQ: FDMT) was reported by SVB Leerink on Friday, May 13, 2022. The analyst firm set a price target for 28.00 expecting FDMT to rise to within 12 months (a possible 258.51% upside). 2 analyst firms have reported ratings in the last year.

Q
Current Stock Price for 4D Molecular Therapeutics (FDMT)?
A

The stock price for 4D Molecular Therapeutics (NASDAQ: FDMT) is $7.81 last updated May 20, 2022, 8:00 PM UTC.

Q
Does 4D Molecular Therapeutics (FDMT) pay a dividend?
A

There are no upcoming dividends for 4D Molecular Therapeutics.

Q
When is 4D Molecular Therapeutics (NASDAQ:FDMT) reporting earnings?
A

4D Molecular Therapeutics’s Q2 earnings are confirmed for Thursday, August 11, 2022.

Q
Is 4D Molecular Therapeutics (FDMT) going to split?
A

There is no upcoming split for 4D Molecular Therapeutics.

Q
What sector and industry does 4D Molecular Therapeutics (FDMT) operate in?
A

4D Molecular Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.